Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14932583 | 0.87 | L3MBTL1 (0.41) | HTTL3MBTL1ALDH1A1ABCB11CYP1A2 | |
| SCHEMBL17315789 | 0.86 | KDM4E (0.38) | HTTL3MBTL1ALDH1A1KDM4EKMT2A | |
| SCHEMBL17315815 | 0.86 | KDM4E (0.38) | L3MBTL1ALDH1A1CYP1A2CYP3A4HPGD | |
| SCHEMBL17622561 | 0.83 | KDM4E (0.39) | L3MBTL1ALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL17315810 | 0.83 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL15999650 | 0.79 | L3MBTL1 (0.41) | HTTL3MBTL1ALDH1A1ABCB11CYP1A2 | |
| SCHEMBL16552188 | 0.77 | L3MBTL1 (0.40) | L3MBTL1ALDH1A1ABCB11CYP1A2CYP3A4 | |
| SCHEMBL14932582 | 0.77 | L3MBTL1 (0.57) | L3MBTL1ALDH1A1CYP1A2CYP3A4HPGD | |
| SCHEMBL20406660 | 0.75 | CYP3A4 (0.40) | L3MBTL1ALDH1A1CYP3A4HPGDCNR2 | |
| SCHEMBL20271838 | 0.75 | L3MBTL1 (0.41) | HTTL3MBTL1ALDH1A1ABCB11CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10420768-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2019-09-24 | — | — | US | disclosed |
| US-10420768-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2019-09-24 | — | — | US | disclosed |
| EP-3194403-B1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS CAYMAN LTD (KY) | 2019-02-06 | — | — | EP | disclosed |
| EP-3152213-B1 | DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS CAYMAN LTD (KY) | 2018-10-31 | — | — | EP | disclosed |
| US-20180303834-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2018-10-25 | — | — | US | disclosed |
| US-10030026-B2 | Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2018-07-24 | — | — | US | disclosed |
| US-10030026-B2 | Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2018-07-24 | — | — | US | disclosed |
| US-10030026-B2 | Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2018-07-24 | — | — | US | disclosed |
| US-9968610-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (US) | 2018-05-15 | — | — | US | disclosed |
| US-9968610-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170101412-A1 | DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-04-13 | — | — | US | disclosed |
| US-20170101412-A1 | DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-04-13 | — | — | US | disclosed |
| EP-3152213-A1 | DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | Rugen Holdings (Cayman) Limited (KY) | 2017-04-12 | — | — | EP | disclosed |
| US-9567341-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-02-14 | — | — | US | disclosed |
| US-9567341-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-02-14 | — | — | US | disclosed |
| US-9567341-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-02-14 | — | — | US | disclosed |
| US-20160075713-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2016-03-17 | — | — | US | disclosed |
| US-20160075713-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2016-03-17 | — | — | US | disclosed |
| WO-2015187845-A1 | DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015187845-A1 | DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10030026-B2 | Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists | GRIN1, GRIN2A, GRIN2B | S1PR1 417/4885S1PR3 519/4885HTT 840/4885 |
| US-10420768-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | GRIN1, GRIN2A, GRIN2B | S1PR1 647/4885S1PR3 850/4885HTT 1542/4885 |
| US-20160075713-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN1, GRIN2A, GRIN2B | S1PR1 647/4885S1PR3 850/4885HTT 1542/4885 |
| US-20170101412-A1 | DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN1, GRIN2A, GRIN2B | S1PR1 417/4885S1PR3 519/4885HTT 840/4885 |
| US-20180303834-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN1, GRIN2A, GRIN2B | S1PR1 647/4885S1PR3 850/4885HTT 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.